Publication Name	World Journal of Gastroenterology
Manuscript ID	6460
Country	United Kingdom

Received	2013-10-19 10:33
Peer-Review Started	2013-10-22 08:54
To Make the First Decision	2013-12-26 11:38
Return for Revision	2013-12-26 18:31
Revised	2014-01-15 18:16
Second Decision	2014-04-03 10:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-03 11:26
Articles in Press	2014-05-23 10:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-16 15:36
Publish the Manuscript Online	2014-07-14 17:39

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Research & Experimental Medicine
Manuscript Type	Topic Highlights
Article Title	Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation
Manuscript Source	Invited Manuscript
All Author List	Stacey J Coleman, Jennifer Watt, Prabhu Arumugam, Leonardo Solaini, Elisabeta Carapuca, Mohammed Ghallab, Richard P Grose and Hemant M Kocher
Funding Agency and Grant Number
Corresponding Author	Hemant M Kocher, MS, MD, FRCS, Centre for Tumour Biology, Barts Cancer Institute - a CR-UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. h.kocher@qmul.ac.uk
Key Words	3D organotypic model; Pancreatic cancer; Pancreatic stellate cell; Stroma; Preclinical models
Core Tip	Pancreatic cancer carries a terrible prognosis, as the fourth most common cause of cancer death in the Western world. One of the reasons no effective treatment has been developed in the past decade may in part, be explained by the influences exerted by the tumour microenvironment. The tumour stroma cross-talk in pancreatic cancer can influence chemotherapy delivery and response rate. Organotypic models of pancreatic cancer allow new therapies that can target the cancer, the stromal compartment or both to be tested in a model that mirrors the in vivo situation and can help improve patient prognosis.
Publish Date	2014-07-14 17:39
Citation	Coleman SJ, Watt J, Arumugam P, Solaini L, Carapuca E, Ghallab M, Grose RP, Kocher HM. Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. World J Gastroenterol 2014; 20(26): 8471-8481
URL	http://www.wjgnet.com/1007-9327/full/v20/i26/8471.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i26.8471

Full Article (PDF)	WJG-20-8471.pdf
Full Article (Word)	WJG-20-8471.doc
Manuscript File	6460-Review.doc
Answering Reviewers	6460-Answering reviewers.pdf
Copyright License Agreement	6460-Copyright assignment.pdf
Peer-review Report	6460-Peer review(s).pdf
Scientific Editor Work List	6460-Scientific editor work list.doc